337 related articles for article (PubMed ID: 33374595)
1. TIME Is a Great Healer-Targeting Myeloid Cells in the Tumor Immune Microenvironment to Improve Triple-Negative Breast Cancer Outcomes.
Singh S; Zhang XHF; Rosen JM
Cells; 2020 Dec; 10(1):. PubMed ID: 33374595
[TBL] [Abstract][Full Text] [Related]
2. Alteration of functionality and differentiation directed by changing gene expression patterns in myeloid-derived suppressor cells (MDSCs) in tumor microenvironment and bone marrow through early to terminal phase of tumor progression.
Mahanti K; Saha J; Sarkar D; Pramanik A; Roy Chattopadhyay N; Bhattacharyya S
J Leukoc Biol; 2024 Apr; 115(5):958-984. PubMed ID: 38236200
[TBL] [Abstract][Full Text] [Related]
3. Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms.
Kim IS; Gao Y; Welte T; Wang H; Liu J; Janghorban M; Sheng K; Niu Y; Goldstein A; Zhao N; Bado I; Lo HC; Toneff MJ; Nguyen T; Bu W; Jiang W; Arnold J; Gu F; He J; Jebakumar D; Walker K; Li Y; Mo Q; Westbrook TF; Zong C; Rao A; Sreekumar A; Rosen JM; Zhang XH
Nat Cell Biol; 2019 Sep; 21(9):1113-1126. PubMed ID: 31451770
[TBL] [Abstract][Full Text] [Related]
4. Guardians and Mediators of Metastasis: Exploring T Lymphocytes, Myeloid-Derived Suppressor Cells, and Tumor-Associated Macrophages in the Breast Cancer Microenvironment.
Ruocco MR; Gisonna A; Acampora V; D'Agostino A; Carrese B; Santoro J; Venuta A; Nasso R; Rocco N; Russo D; Cavaliere A; Altobelli GG; Masone S; Avagliano A; Arcucci A; Fiume G
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892411
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting with DABIL-4 depletes myeloid suppressor cells in 4T1 triple-negative breast cancer model.
Parveen S; Siddharth S; Cheung LS; Kumar A; Shen J; Murphy JR; Sharma D; Bishai WR
Mol Oncol; 2021 May; 15(5):1330-1344. PubMed ID: 33682324
[TBL] [Abstract][Full Text] [Related]
6. Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.
Clappaert EJ; Murgaski A; Van Damme H; Kiss M; Laoui D
Front Immunol; 2018; 9():2250. PubMed ID: 30349530
[TBL] [Abstract][Full Text] [Related]
7. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.
Nakamura K; Smyth MJ
Cell Mol Immunol; 2020 Jan; 17(1):1-12. PubMed ID: 31611651
[TBL] [Abstract][Full Text] [Related]
8. The Immunosuppressive Microenvironment in BRCA1-IRIS-Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages.
Sami E; Paul BT; Koziol JA; ElShamy WM
Cancer Res; 2020 Mar; 80(5):1102-1117. PubMed ID: 31911557
[TBL] [Abstract][Full Text] [Related]
9. Blockade of p38 kinase impedes the mobilization of protumorigenic myeloid populations to impact breast cancer metastasis.
Zonneville J; Colligan S; Grant S; Miller A; Wallace P; Abrams SI; Bakin AV
Int J Cancer; 2020 Oct; 147(8):2279-2292. PubMed ID: 32452014
[TBL] [Abstract][Full Text] [Related]
10. Special Education.
Kozutsumi H
Oncologist; 1996; 1(1 & 2):116-118. PubMed ID: 10387976
[TBL] [Abstract][Full Text] [Related]
11. Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer.
Kajihara N; Kobayashi T; Otsuka R; Nio-Kobayashi J; Oshino T; Takahashi M; Imanishi S; Hashimoto A; Wada H; Seino KI
Cancer Immunol Immunother; 2023 Apr; 72(4):851-864. PubMed ID: 36104597
[TBL] [Abstract][Full Text] [Related]
12. Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia.
Hanna BS; Öztürk S; Seiffert M
Mol Immunol; 2019 Jun; 110():77-87. PubMed ID: 29173971
[TBL] [Abstract][Full Text] [Related]
13. Triple negative breast cancer - prognostic role of immune-related factors: a systematic review.
Stovgaard ES; Nielsen D; Hogdall E; Balslev E
Acta Oncol; 2018 Jan; 57(1):74-82. PubMed ID: 29168430
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
[TBL] [Abstract][Full Text] [Related]
15. Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer.
Dominguez C; McCampbell KK; David JM; Palena C
JCI Insight; 2017 Nov; 2(21):. PubMed ID: 29093275
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer cells promote CD169
Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y
Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052
[TBL] [Abstract][Full Text] [Related]
17. PERK-Phosphorylated eIF2α Pathway Suppresses Tumor Metastasis Through Downregulating Expression of Programmed Death Ligand 1 and CXCL5 in Triple-Negative Breast Cancer.
Zou W; Bai Y; Wang X; Cheng K; Sun H; Zhang G; Wang X; Yang Z
Cancer Biother Radiopharm; 2017 Oct; 32(8):282-287. PubMed ID: 29053414
[TBL] [Abstract][Full Text] [Related]
18. Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies.
Palumbo GA; Parrinello NL; Giallongo C; D'Amico E; Zanghì A; Puglisi F; Conticello C; Chiarenza A; Tibullo D; Raimondo FD; Romano A
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683978
[TBL] [Abstract][Full Text] [Related]
19. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities.
Lu C; Rong D; Zhang B; Zheng W; Wang X; Chen Z; Tang W
Mol Cancer; 2019 Aug; 18(1):130. PubMed ID: 31464625
[TBL] [Abstract][Full Text] [Related]
20. Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets.
Müller L; Tunger A; Plesca I; Wehner R; Temme A; Westphal D; Meier F; Bachmann M; Schmitz M
Front Immunol; 2020; 11():140. PubMed ID: 32117287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
